CIK 0001826457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Exercise or conversion 10b5-1 | +6,000 | $6.14 | $37K | 73,845 |
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Sale 10b5-1 | −5,600 | $23.25 | $130K | 68,245 |
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Sale 10b5-1 | −400 | $24.13 | $10K | 67,845 |
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −6,000 | 197,290 | ||
| 2026-06-23 | Townson Sharon Chief Scientific Officer | Exercise or conversion 10b5-1 | +3,000 | $6.14 | $18K | 70,845 |
| 2026-06-23 | Townson Sharon Chief Scientific Officer | Sale 10b5-1 | −3,000 | $20.00 | $60K | 67,845 |
| 2026-06-23 | Townson Sharon Chief Scientific Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −3,000 | 203,290 | ||
| 2026-06-17 | Townson Sharon Chief Scientific Officer | Exercise or conversion 10b5-1 | +3,000 | $6.14 | $18K | 70,845 |
| 2026-06-17 | Townson Sharon Chief Scientific Officer | Sale 10b5-1 | −3,000 | $19.00 | $57K | 67,845 |
| 2026-06-17 | Townson Sharon Chief Scientific Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −3,000 | 206,290 | ||
| 2026-05-29 | Townson Sharon Chief Scientific Officer | Exercise or conversion 10b5-1 | +6,000 | $6.14 | $37K | 73,845 |
| 2026-05-29 | Townson Sharon Chief Scientific Officer | Sale 10b5-1 | −6,000 | $19.87 | $119K | 67,845 |
| 2026-05-29 | Townson Sharon Chief Scientific Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −6,000 | 209,290 | ||
| 2026-01-05 | Townson Sharon Chief Scientific Officer | Sale | −3,155 | $15.17 | $48K | 67,845 |
| 2026-01-02 | Townson Sharon Chief Scientific Officer | Grant or award | +35,000 | 71,000 | ||
| 2026-01-02 | Townson Sharon Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +158,000 | 158,000 | ||
| 2025-01-02 | Townson Sharon Chief Scientific Officer | Grant or award | +36,000 | 36,000 | ||
| 2025-01-02 | Townson Sharon Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +161,000 | 161,000 | ||
| 2024-06-03 | Townson Sharon Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2023-01-03 | Townson Sharon Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +78,550 | 78,550 |
Page 1 of 2 · 21 trades